Patents Examined by Howard E. Schain
  • Hyaluronic acid-containing aqueous solution or aqueous dispersion of collagen
    Patent number: 5137875
    Abstract: A hyaluronic acid-containing aqueous solution or aqueous dispersion of collagen having a pH of from about 6.5 to about 8.0 and an osmolality of from about 230 to about 320 mOsm/kgH.sub.2 O. The aqueous solution or the aqueous dispersion of collagen is useful as an agent for correction and reparation of a depressed part of or a void in soft tissue of mammals.
    Type: Grant
    Filed: April 18, 1989
    Date of Patent: August 11, 1992
    Assignees: Shiseido Co., Ltd., Koken Co., Ltd.
    Inventors: Makoto Tsunenaga, Naoki Tominaga, Toshio Nishiyama, Toru Yamashita, Mutsumi Fukuyama, Teruo Miyata, Masayasu Furuse
  • Porous particles in preparations involving immiscible phases
    Patent number: 5135740
    Abstract: Immiscible phases, particularly polar and non-polar liquids, semi-solids or solids, are combined in a composition where one is finely dispersed throughout the other without reliance upon emulsifying agents to either create or stabilize the dispersion. The composition is formed by placing the discontinuous phase in the pores of solid inert porous particles, in which the pores are in the form of an interconnected network open to the exterior of the particles to provide interfacial contact with the continuous phase. The particles are then dispersed in the continuous phase. The concept is applicable to oil-in-water and water-in-oil type dispersions, and the disadvantages and shortcomings of emulsifying agents are entirely avoided.
    Type: Grant
    Filed: October 2, 1989
    Date of Patent: August 4, 1992
    Assignee: Advanced Polymer Systems, Inc.
    Inventors: Martin Katz, Chung-Heng Cheng
  • Crystalline n-(s-3-methylheptanoyl)-D-gamma-glutamyl-glycyl-D-alanine, and processes and intermediates therefor
    Patent number: 5136020
    Abstract: A process and intermediates for the manufacture of S-3-methylheptanoic acid from S-citronellol; a novel crystalline form of immunoregulatory N-(S-3-methylheptanoyl)-D-gamma-glutamyl-glycyl-D-alanine, an immunoregulatory agent; and an improved process and intermediates therefor.
    Type: Grant
    Filed: February 21, 1989
    Date of Patent: August 4, 1992
    Assignee: Pfizer Inc.
    Inventor: Charles W. Murtiashaw
  • Nutrient composition
    Patent number: 5134125
    Abstract: The present invention relates to nutrient compositions for mammals comprising L-glutamyl-L-glutamine.
    Type: Grant
    Filed: October 19, 1990
    Date of Patent: July 28, 1992
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Takahiro Hara, Tadayasu Furukawa
  • Processes and intermediates for N-(S-3-alkyl-heptanoyl)-D-gamma-glutamyl-D-alanine
    Patent number: 5134225
    Abstract: Immunoregulatory N-(S-3-alkyl-4-heptenoyl)- and N-(S-3-alkylheptanoyl)-D-gamma-glutamyl-glycyl-D-alanine and esters thereof are synthesized via R-trans-2-hexen-4-ols, R-3-alkyl-4-heptenoic acid and S-3-alkylheptanoic acid.
    Type: Grant
    Filed: February 21, 1989
    Date of Patent: July 28, 1992
    Assignee: Pfizer Inc.
    Inventor: Charles W. Murtiashaw
  • Treatment of inflammation using 358 substituted alpha-antitrypsin
    Patent number: 5134119
    Abstract: A method for the prophylaxis or direct treatment of mast cell implicated skin inflammation in a patient which comprises topically administering an effective amount of an analog of alpha 1-antitrypsin, its salts or derivatives, and compositions thereof.
    Type: Grant
    Filed: January 18, 1991
    Date of Patent: July 28, 1992
    Inventors: Lezdey John, Allen Wachter
  • Purified inducible nitric oxide synthase flavoprotein
    Patent number: 5132407
    Abstract: Inducible nitric oxide (NO) synthase flavoprotein purified to an activity more than 400-fold from activated mouse macrophage cell line is water soluble, has a denatured molecular mass as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis under reducing conditions ranging from 125 to 135 kDa, has a molecular mass in catalytically active form of about 250 kDa, does not require added calcium ions or calmodulin for activity, and on heat denaturation releases flavin adenine dinucleotide in an amount of 1.1.+-.0.1 mol per mol of 130 kDa polypeptide subunit of the purified flavoprotein and flavin mononucleotide in an amount of at least 0.55.+-.0.04 mol per mol of 130 kDa polypeptide subunit of the purified flavoprotein.
    Type: Grant
    Filed: September 26, 1991
    Date of Patent: July 21, 1992
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Dennis J. Stuehr, Carl F. Nathan
  • Method of purifying human serum albumin using organic carboxylic acids and acetyl tryptophan
    Patent number: 5132404
    Abstract: A method of purifying human serum albumin which comprises subjecting human serum albumin-containing solution to heat treatment of about 50.degree.-70.degree. C. for 1-5 hours in the presence of acetyltryptophan and/or an organic carboxylic acid with 6-12 carbon atoms or a salt thereof.
    Type: Grant
    Filed: September 18, 1990
    Date of Patent: July 21, 1992
    Assignee: Green Cross Corporation
    Inventors: Wataru Ohtani, Akinori Sumi, Takao Ohmura, Yahiro Uemura
  • Methods of treating disorders which cause conglutinin deficiency
    Patent number: 5132287
    Abstract: Human conglutinin, polyclonal, and monoclonal antibodies raised against human conglutinin, and their uses in therapy and diagnosis are described.Human conglutinin was obtained from human plasma by affinity chromatography with anti-bovine conglutinin antibody, has a relative molecular weight of 330 and 40 K unreduced and 66 K reduced as measured by SDS-PAGE, shows calcium-dependent and sugar inhibitable binding to complement-reacted immune complexes and zymosan, and immunological cross-reaction with anti-bovine conglutinin antibody.
    Type: Grant
    Filed: November 27, 1989
    Date of Patent: July 21, 1992
    Assignee: Novo Industri A/S
    Inventor: Jens C. Jensenius
  • Method of producing immunoglobulin preparations for intravenous injection
    Patent number: 5132406
    Abstract: A method of producing immunoglobulin preparations for intravenous injection which starts with an immunoblobulin-containing fraction and comprises the treatment steps of:(a) treating said fraction with 4-10 weight/volume percent of polyethylene glycol having a molecular weight of 1,000-10,000 under conditions of pH 4-6, ion strength 0.0001-0.1M and temperature 0.degree.-4.degree. C. and recovering the supernatant,(b) treating the supernatant obtained in step (a) with 10-15 weight/volume percent of polyethylene glycol having a molecular weight of 1,000-10,000 under conditions of pH 6-9, ion strength 0.0001-0.1M and temperature 0.degree.-4.degree. C. and recovering the resulting precipitate, and(c) heat-treating, in any desired step, said immunoglobulin in the presence of a stabilizer under conditions sufficient to inactivate contaminant viruses.
    Type: Grant
    Filed: May 5, 1989
    Date of Patent: July 21, 1992
    Assignee: The Green Cross Corporation
    Inventors: Yahiro Uemura, Katuhiro Uriyu, Kazuo Takechi, Yutaka Hirao, Tadakazu Suyama
  • Compositions for and methods of treating muscle degeneration and weakness
    Patent number: 5130141
    Abstract: Compositions for and methods of treating muscle weakness and degeneration are described. Such compositions include myogenic cells which are administered by the described methods to one or more affected muscles.
    Type: Grant
    Filed: May 30, 1991
    Date of Patent: July 14, 1992
    Inventors: Peter K. Law, Tena G. Goodwin
  • Stabilized compositions containing epidermal growth factor
    Patent number: 5130298
    Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically effective amount of human epidermal growth factor (EGF) and an amount of a pharmaceutically acceptable metal cation, such as zinc, which is sufficient to prevent the degradation of said EGF.
    Type: Grant
    Filed: May 16, 1989
    Date of Patent: July 14, 1992
    Assignee: Ethicon, Inc.
    Inventors: John K. Cini, Amy L. Finkenaur
  • Agent for therapy
    Patent number: 5128322
    Abstract: There is provided a novel therapeutic agent for use in the prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy, as well as a method of prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy with the therapeutic agent, and a method of prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy with the therapeutic agent in combination with one or more other agents indicated for the treatment of acute nonlymphocytic leukemia.
    Type: Grant
    Filed: June 25, 1991
    Date of Patent: July 7, 1992
    Assignee: Imperial Chemical Industries plc
    Inventor: Mitchell Glass
  • Immunoglobulin-G-containing fraction
    Patent number: 5122373
    Abstract: An immunoglobulin-G-containing fraction from human or animal plasma comprising monomeric IgG molecules as well as at least 70% gammaglobulins, destined for intravenous application.The fraction has a low anticomplementary activity and is substantially free of vasoactive and leucopenically active as well as bronchospastic substances.
    Type: Grant
    Filed: August 20, 1990
    Date of Patent: June 16, 1992
    Assignee: Immuno Aktiengesellschaft
    Inventors: Johann Eibl, Yendra Linnau, Otto Schwarz
  • Nutrient composition containing dipeptides and method for administering the same
    Patent number: 5122515
    Abstract: This invention relates to a nutrient composition containing a dipeptide and method for administering the same. Particularly, this invention relates to a dipeptide tyrosyl-arginine, comprised of the amino acids tyrosine and arginine and the use of this dipeptide as a nutrient supplement to intravenous nutrition.
    Type: Grant
    Filed: June 19, 1990
    Date of Patent: June 16, 1992
    Inventors: Ross C. Smith, Brian P. Walker
  • Process for treatment of allergies
    Patent number: 5122372
    Abstract: This invention relates to the immunotherapeutic treatment of allergies. More particularly, this invention relates to a process for treating allergies by administering to a mammal a pharmaceutically effective amount of gamma interferon.
    Type: Grant
    Filed: April 30, 1987
    Date of Patent: June 16, 1992
    Assignee: Biogen, Inc.
    Inventors: Anthony J. Pinching, Jacqueline M. Parkin
  • Fish growth using bovine placental lactogen
    Patent number: 5122513
    Abstract: A method is described for increasing growth of fish which comprises administering bovine placental lactogen.
    Type: Grant
    Filed: March 19, 1991
    Date of Patent: June 16, 1992
    Assignee: Monsanto Company
    Inventors: Robert H. Devlin, Edward M. Donaldson, Ernest G. Jaworski, Gwenn G. Krivi
  • Method for the diagnosis and treatment of human granulomatous inflammatory disease
    Patent number: 5120714
    Abstract: A method for the diagnosis of human granulomatous inflammatory disease comprising determining the level of Granuloma Enhancing Factor (GEF) activity in a bodily fluid and comparing said level to established diagnostic levels is provided. Methods for treatment of human granulomatous diseases are also provided.
    Type: Grant
    Filed: October 17, 1990
    Date of Patent: June 9, 1992
    Assignee: Thomas Jefferson University
    Inventor: Herbert Patrick
  • Bacillus thuringiensis var. donegani preparate or toxin obtained from it, endowed with insecticide activity against Coleoptera
    Patent number: 5120536
    Abstract: Disclosed is a Bacillus thuringiensis var. donegani, pathotype C, NCIMB 42 and a preparate or a toxin obtained from it, endowed with insecticide activity against Coleoptera.
    Type: Grant
    Filed: July 31, 1990
    Date of Patent: June 9, 1992
    Assignee: Presidenza del Consiglio dei Ministri-Ufficio del Ministro per il Coordinamento delle Iniziative per la Ricerca Scientificia e Tecnologica
    Inventors: Dante Cidaria, Andrea Cappai, Adriana Vallesi, Vincenzo Caprioli, Giorgio Pirali
  • Bone growth factors and inhibitors of bone resorption for promoting bone formation
    Patent number: 5118667
    Abstract: Bone growth factors are used to stimulate new bone formation when administered with agents that inhibit bone resorption. These therapeutic combinations result in an enhanced rate of bone formation with an increase in bone mass.
    Type: Grant
    Filed: May 3, 1991
    Date of Patent: June 2, 1992
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Steven W. Adams, Rosa Armstrong, David Rosen